Walvax expands into non-patient micro-ecological health market

Walvax Biotechnology amended its exclusive sub-licensing agreement with Notitia Biotechnologies Company to expand into non-patient populations for micro-ecological health technology. The expanded agreement covers exclusive development, manufacturing, and commercialization rights in mainland China, Hong Kong, and Macau.

Financial terms include an initial $1 million payment, followed by $200,000 upon amendment signing, and $300,000 twelve months later.

Separately, Walvax is seeking bank credit lines totaling 2.95 billion yuan from various banks for operations and research and development.